[Amifostin in protection of kidney from cisplatinum injury]

Author(s): Cui H, Zhang S, Li P, Guan Z, Sun X, Shen K, Wu M, Hu X, Liu S, Di L, Zhang S

Affiliation(s): China and Japan Friendship Hospital, Beijing You An Hospital, Beijing 10029, China.

Publication date & source: 2002-01, Zhonghua Zhong Liu Za Zhi., 24(1):48-50.

Publication type: Clinical Trial; Randomized Controlled Trial

OBJECTIVE: To evaluate Amifostin's effect on protecting kidney from cisplatinum (DDP) injury and its adverse reactions and safety. METHODS: 193 Patients were divided into two groups randomly: 102 in group A (treatment group) and 91 in group B (control group). Indexes such as blood routine, blood calcium, liver function, blood urea nitrogen (BUN), cretinine (C), and urinary N-acetyl-beta-D-glucosaminidase (NAG)/C and micro-albumin (MAB/C) were monitored at different intervals before or after treatment. RESULTS: In the two courses of treatment in both groups, the deviation (D) values of MAB/C before treatment and on D2 in group A were lower than those in grop B (P < 0.05), so were those before treatment and on D4, D6, D10 and D14 (P < 0.01). The D-values of NAG/C before treatment and on D4, D6, D10 and D14 in the first course of group A were obviously lower than those on the corresponding days in group B (P < 0.01), so were those before treatment and on D2, D4, D6, D10 and D14 in the second course (P < 0.01). CONCLUSION: The reduction of MAB/C and NAG/C by Amifostin in group A demonstrates that: Amifostin is able to effectively protect the renal function, regardless of the type of tumor. In contrast with group B, Amifostin in group A shows no protection for tumor in lung cancer and ovarian cancer. The main side effects of Amifostin are mild hypotension, nausea, vomiting and hypocalcemia in some patients.